Background
S100P, a binder of receptors for advanced-glycation end products, is an established biomarker of many types of cancer. However, data regarding its role in diabetes and diabetic peripheral neuropathy (DPN) are unclear.
Aim
The aim of this work was to study the relationship between serum S100P and DPN in patients with type-2 diabetes mellitus (T2DM).
Participants and methods
This cross-sectional study included a total of 90 subjects divided into three groups: 30 patients with T2DM complicated with peripheral neuropathy (group A), 30 patients with T2DM without peripheral neuropathy (group B), and 30 subjects as healthy-control group (group C). All patients with T2DM were assessed for peripheral neuropathy using Michigan neuropathy screening instruments and nerve-conduction study was done to diagnose subclinical neuropathy. Serum S100P was assessed by enzyme-linked immunosorbent assay technique.
Results
Mean serum S100P levels in group A and group B were significantly lower compared with group C (<0.001 for both comparisons). However, there was no significant difference in mean serum S100P levels between groups A and B (=0.394).
Conclusion
Serum S100P is significantly low in T2DM with no significant association with DPN.